Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • The personalized neoantigen vaccine Neo-PV-01 plus nivolumab is feasible and safe • NEO-PV-01 plus nivolumab stimulates durable neoantigen-specific T cell reactivity • NEO-PV-01-specific T cells have cytotoxic potential and can traffic to the tumor • NEO-PV-01 induces epitope spreading consistent with vaccine-mediated tumor cytotoxicity Summary Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
